Shares of Human Genome Sciences Inc. (Nasdaq: HGSI) leaped $6.96 to $10.28 after the drug maker reported positive results for its lupus drug treatment. The company has partnered with GlaxoSmithKline plc (NYSE: GSK) to develop and market the product. Shares of GlaxoSmithKline climbed $1.18 to $37.54.
Upbeat Trial Results For Human Genome Sciences
July 20, 2009 at 12:04 PM EDT
